A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors
Advanced Solid Tumors
BIOLOGICAL: T3011 high dose|BIOLOGICAL: T3011 middle dose|BIOLOGICAL: T3011 low dose
Incidence of Treatment-Emergent Adverse Events, Adverse event type, incidence, duration, Approximately 2years|Objective response rate(ORR), Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1, Approximately 2years
Disease control rate (DCR), DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease, Approximately 2years|Duration of remission (DOR), DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response to the date of disease progression per RECIST v1.1 or death from any cause., Approximately 2years|Progression-free survival (PFS), From the start date of study treatment to the date of progression disease or death , whichever occurred first., Approximately 2years|Overall Survival (OS), Determination of the overall survival time of all patients, Approximately 2years
This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors